Masimo delivered Q3 results that mostly aligned with guidance, yet it faces challenges in its non-healthcare segment.

Masimo (NASDAQ:MASI) is set to give its latest quarterly earnings report on Tuesday, 2024-11-05. Here's what investors need to know before the announcement. Analysts estimate that Masimo will ...

Apple and Masimo are back in a California court this week for a bench trial that will see Masimo arguing that Apple illegally poached its employees and stole trade secrets when developing the ...

Masimo MASI2.20%increase; green up pointing triangle said Joe Kiani, who previously informed the board of his decision to resign as chief executive, has been terminated by the company. Kiani’s ...

According to a regulatory filing, following a review by outside counsel, on October 24, 2024, the Board of Directors of Masimo (MASI) adopted resolutions to terminate the employment of Masimo’s ...

The $250 (yep, there’s no missing ‘M’ from the end of that number) Apple was awarded in its patent infringement case against Masimo might seem amusing – as John Gruber wryly noted ...

Ladies and gentlemen, good afternoon, and welcome to Masimo's Third Quarter 2024 Earnings Conference Call. The company's press release is available at www.masimo.com. At this time, all lines have ...

Apple is fighting a running legal battle with the health tech company Masimo over pulse oximetry technology and smartwatch design patents. A jury in a federal trial awarded Apple a paltry $250 ...

Apple and Masimo's patent and trade secret dispute has intensified through lawsuits as Apple defends its innovations and Masimo's claims are rejected in court. Apple and medical equipment maker ...

The consensus rating for Masimo is Buy, based on 2 analyst ratings. With an average one-year price target of $167.5, there's a potential 16.14% upside.